Table 3

Univariate analysis of effect of therapeutic interventions in patients with and without AKI.

NO AKI (n = 445)

AKI (n = 243)

p value


Wait list (any time)


Aminoglycoside

55 (12%)

24 (10%)

0.33


Inotrope use

367 (82%)

198 (81%)

0.75


Time of surgery

407(91%)

213(87%)

0.10


Anhepatic phase (Cross clamp)

421(95%)

228(94%)

0.73


Post operative

414(93%)

224(92%)

0.75


Pre-operative


Loop diuretic

172 (38%)

108 (44%)

0.14


Spironolactone

226 (51%)

133 (53%)

0.30


Intra-operative


Albumin (ml)

1059 ± 1311

1199 ± 1509

0.50


Colloid (ml)

2413 ± 2400

2428 ± 3336

0.30


Packed red blood cells (ml)

3440 ± 3281

3974 ± 3758

0.003


Platelets (ml)

813 ± 98

1082 ± 1118

0.0002


Cryoprecipitate (ml)

228 ± 490

212 ± 405

0.90


Fresh frozen plasma (ml)

3695 ± 2759

4582 ± 3121

0.00002


Venovenous bypass

270 (61%)

128 (53%)

0.044


Post-operative


Loop diuretic use

334 (75%)

208 (85%)

0.001


Cyclosporin use

330 (74%)

150 (61%)

0.001


Tacrolimus use

46 (10%)

42 (17%)

0.012


Cyclosporin level, day 1

298 ± 220

269 ± 233

0.09


Cyclosporin level, day 3

816 ± 517

793 ± 548

0.75


Tacrolimus level, day 1

7.8 ± 11.0

6.2 ± 5.3

0.58


Tacrolimus level, day 3

9.2 ± 13.0

15.6 ± 18.0

0.14


Iglesias et al. BMC Nephrology 2010 11:30   doi:10.1186/1471-2369-11-30

Open Data